Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Q2 2022 Earnings Conference Call August 1, 2022 8:00 AM ET

Company Participants

Matt Calistri - Vice President of Corporate Strategy and Investor Relations

Tony Coles - Chairperson and Chief Executive Officer

Ray Sanchez - Chief Medical Officer

John Renger - Chief Scientific Officer

Mark Bodenrader - Interim Chief Financial Officer

A. Ceesay - President

Conference Call Participants

Michael Yee - Jefferies

Matthew Harrison - Morgan Stanley

Paul Matteis - Stifel

Tiffany Sun - JPMorgan

Douglas Tsao - H.C. Wainwright

Graig Suvannavejh - Mizuho

Operator

Good morning. And welcome to the Cerevel Therapeutics Second Quarter 2022 Financial Results Conference Call. At this time, all participants are in listen-only mode. Later, you will have the opportunity to ask questions during the Q&A portion of the call. Please note that this call may be recorded.

I will now hand the call over to Matt Calistri, Vice President of Corporate Strategy and Investor Relations.

Matt Calistri

Thank you. Good morning, everyone. We appreciate you joining us for our second quarter 2022 earnings call. On today's call, you'll be hearing from Dr. Tony Coles, our Chairperson and Chief Executive Officer; Dr. Ray Sanchez, our Chief Medical Officer; Dr. John Renger, our Chief Scientific Officer; and Mark Bodenrader, our Interim Chief Financial Officer. A. Ceesay, our President, will join us for Q&A.

During our call today, please refer to our press release from this morning detailing our Q2 2020 performance, as well as our updated corporate presentation, both of which are available on our website. I'd like to remind you that we will be making forward-looking statements that reflect our current views related to, among other things, the potential attributes and benefits of our product candidates and the format and timing of our product development activities and clinical trials. We strongly encourage you to review the information that we file with the SEC regarding specific risks and uncertainties.

I will now hand the call over to Dr. Tony Coles, Chairperson and CEO of Cerevel to provide an overview of our achievements and outlook.

Tony Coles

Good morning, everyone, and thank you for joining us for our second quarter 2022 business results call. At Cerevel, it's our aspiration to become the leader in neuroscience company and we are certainly well on our way of achieving this distinction with a broad and deep pipeline of new programs, compelling early data in schizophrenia, which has led us to initiate a potentially pivotal large Phase II program for emraclidine, 5 new data readouts expected next year and a robust set of mid to late-stage programs that have the potential to bring transformative medicines to millions of people living with schizophrenia, Parkinson's, epilepsy and dementia-related apathy.